Hyper-scaling platform Kubeark raises $2.8m pre-seed round to help SaaSify software products and enable cloud adoption
1.2.2023 15:00:00 CET | Business Wire | Press Release
Kubeark, an open and infrastructure-agnostic platform which has made it its mission to support enterprises fix their scalability, delivery and lifecycle management challenges, has raised $2.8 millionin a pre-seed funding round. The investment round was led by Credo Ventures, with participation from Seedcamp, LAUNCHub Ventures, 500 Emerging Europe, and others.
“Cloud computing continues to be an important technology trend, with ever more businesses becoming cloud-native. In the process, a major persisting challenge they face is to make applications more scalable and easier to deploy. We believe Kubeark is addressing this need by abstracting the complexity and allowing the user to define business rules that power the deployment process,” said Ondrej Bartos, Co-founder and General Partner at Credo Ventures.
The pandemic forced CIOs, CFOs and CTOs to implement flexible cloud strategies and compelled businesses everywhere to look at tools that allowed them to take control of their mission-critical workloads and data management. “Software vendors currently struggle with their hybrid cloud infrastructure and the transformation of products from on-premises to cloud on a large scale. Kubeark helps them achieve operational excellence regardless of where their infrastructure resides: on premises, on public, or on private cloud,” Bogdan Nedelcov, Kubeark CEO and Co-founder said. “Our platform ushers in a new era in which software products are delivered as true SaaS products, helping vendors speed time-to-value, hyper-scale their distribution, and SaaSify any piece of software instantly,” he added.
The open, infrastructure-agnostic platform simplifies and innovates the way companies develop business models. With Kubeark, software vendors can remove the complexity of their application development lifecycle by effortlessly deploying, managing and scaling applications on any type of infrastructure, from private or public cloud to on-premises, for both open and closed systems.
The six-strong founding team includes CEO Bogdan Nedelcov, CTO Teofil Harapcea, VP of Engineering Adrian Tudoran, VP of Customer Success George Dumitrascu, VP of Product Bogdan Dumitru, and Mihai Faur (Board Member). Headquartered in New York, Kubeark has offices in Bucharest, Romania, and a team of 20.
“We are excited to back Kubeark, a company founded by an incredibly experienced team with roots at Seedcamp-backed UiPath. Their holistic yet versatile solution has the potential to supercharge scalability in an efficient and secure way,” said Reshma Sohoni, Managing Partner at Seedcamp.
“Almost every SaaS company struggles to deploy and manage different infrastructures for their customers, either battling with a do-it-yourself approach or pushing a one-size-fits-all approach, leaving billions of dollars on the table,” said Enis Hulli, a General Partner at 500 Emerging Europe. “We were immediately impressed with the Kubeark team and believe that they are uniquely positioned to wrap business logic around a Kubernetes as a service offering, tapping a nascent space and an unserved market that can create trillions of dollars in value for their customers.”
The investment will help Kubeark accelerate platform development and build a strong network of global partners in order to advance and scale the adoption of its technology.
About Kubeark
Kubeark is an open, infrastructure-agnostic platform built to scale any software product, which integrates deployment and management into business processes. With Kubeark, software vendors can remove the complexity of their application development lifecycle by effortlessly deploying, managing and scaling applications on any type of infrastructure, from private or public cloud to on-premises, for both open and closed systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005648/en/
Contact information
Media:
Cristina Siscanu
pr@kubeark.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
